Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-279096
Filing Date
2025-11-13
Accepted
2025-11-13 08:35:02
Documents
60
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fate-20250930.htm   iXBRL 10-Q 2958432
2 EX-10.1 fate-ex10_1.htm EX-10.1 41612
3 EX-31.1 fate-ex31_1.htm EX-31.1 13164
4 EX-31.2 fate-ex31_2.htm EX-31.2 12532
5 EX-32.1 fate-ex32_1.htm EX-32.1 12700
  Complete submission text file 0001193125-25-279096.txt   12824064

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fate-20250930.xsd EX-101.SCH 1328849
63 EXTRACTED XBRL INSTANCE DOCUMENT fate-20250930_htm.xml XML 3165903
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 251475610
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)